Ctrl

K

Aceclofenac CR

Class
Nonsteroidal anti-inflammatory drugs
Subclass
Acetates
Generic name
Aceclofenac CR
Brand names
Clanza CR®
Common formulations
Film-coated tablet
Dosage and administration
Adults patients
Treatment
Osteoarthritis • Scapulohumeral, lumbar, hip
•
200 mg PO daily
Periarthritis • Scapulohumeral, lumbar, hip
•
200 mg PO daily
Rheumatoid arthritis
•
200 mg PO daily
Symptomatic relief
Symptomatic relief of rheumatoid arthritis
•
200 mg PO daily
Indications for use
Labeled indications
Adults
•
Treatment of axial spondyloarthritis
•
Treatment of osteoarthritis (scapulohumeral, lumbar, hip)
•
Treatment of periarthritis (scapulohumeral, lumbar, hip)
•
Treatment of rheumatoid arthritis
•
Symptomatic relief of rheumatoid arthritis
Safety risks
Boxed warnings
Acute myocardial infarction, angina, cardiac arrhythmias
•
Use extreme caution with cardiac disease. Assess cardiovascular risk factors before prescribing Aceclofenac, monitor patients closely for signs of cardiovascular events, and consider alternative medications if necessary. Discontinue Aceclofenac, provide appropriate medical intervention and treatment for acute myocardial infarction, angina, or cardiac arrhythmias as per standard medical practice.
Gastritis, gastrointestinal bleeding
•
Use extreme caution with a history of or active gastrointestinal disease. Use with caution, avoid long-term use, and consider gastroprotective measures. Discontinue Aceclofenac, seek medical attention, and manage symptoms and complications as appropriate.
Contraindications
A history of heart attack or stroke
Active peptic ulcer/GI bleeding
Asthma
Salicylate hypersensitivity or NSAID hypersensitivity
•
Patients with a known hypersensitivity to Aceclofenac or other NSAIDs should avoid its use.
Warnings and precautions
Exacerbation of hypertension
•
Use caution with a history of hypertension.
Fluid retention
•
Use caution on diuretics.
Hematologic disorder
•
Use extreme caution with a history of coagulopathy, thrombocytopenia, immunosuppression, or undergoing surgery when a high degree of hemostasis is required. Monitor blood counts regularly during Aceclofenac therapy and discontinue if significant hematologic abnormalities occur. Discontinue Aceclofenac if hematologic disorders such as anemia, leukopenia, or thrombocytopenia develop, and provide appropriate medical management as needed.
Specific populations
Renal impairment
eGFR < 30 mL/min/1.73 m²
•
Do not use. Monitor renal function. due to increased risk of acute kidney injury.
Renal replacement therapy
Continuous renal replacement
•
Do not use.
Intermittent hemodialysis
•
Do not use.
Peritoneal dialysis
•
Do not use.
Hepatic impairment
Child-Pugh A (mild)
•
Use acceptable. No dose adjustment required.
Child-Pugh B (moderate)
•
Use acceptable. No dose adjustment required.
Child-Pugh C (severe)
•
Use with caution. Monitor serum aminotransferases.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Avoid use.
Breastfeeding
Do not use during breastfeeding.
•
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Common 1-10%
•
Gastrointestinal disorders, dizziness, headache, skin rash, somnolence, urticaria
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource